- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03571191
Denosumab Treatment for Fibrous Dysplasia
An Open Label Pilot Study of Denosumab Treatment for Fibrous Dysplasia
Objectives:
The primary objective of this study is to evaluate the effect of denosumab on bone turnover in individuals with fibrous dysplasia (FD). Secondary objectives are to determine the effect of denosumab on bone pain, FD lesion intensity as revealed in 18F-sodium fluoride PET/CT bone scan, and to determine the effect of denosumab discontinuation on bone turnover re-bound after discontinuation.
Study Population:
Up to 14 adult subjects with FD may be enrolled to ensure complete study data on 9 subjects.
Design:
This study is a single center, open label pilot study of once-monthly dosing of denosumab. Subjects will be treated for 6 months, after which they will be followed by an 8-month observation period. A final visit will occur 21 months after denosumab discontinuation. Dosing will be adopted from studies in adults on treatment for giant cell tumors, with denosumab administered at 120 mg per dose every 4 weeks, with loading doses on days 7 and 14 of month 1.
Outcome Measures:
Primary:
Assessment of the effects of denosumab on:
1. Markers of bone turnover:
Beta-crosslaps C-telopeptides (bone resorption marker)
Procollagen-1-propeptide (bone formation marker)
Secondary:
Assessment of the effects of denosumab on:
Bone histomorphometric indices:
Mineralized perimeter
Bone formation rate
Cortical width
Cortical area
Osteoid width
Osteoid perimeter
Mineral apposition rate
Surrogate markers of a direct therapeutic effect of denosumab on FD lesions:
Semi-quantitative changes in RANKL, Ki67 (marker of cell proliferation), p16 (marker of cell senescence), and/or apoptosis index before and after treatment, as assessed by immunohistochemistry
Changes in sentinel lesion intensity, measured quantitatively by uptake on 18Fsodium fluoride PET/CT bone scan.
- FD-related bone pain assessed by the Brief Pain Inventory (Short Form) , a validated self-reporting tool for assessment of pain.
Exploratory Endpoints:
Effect of denosumab initiation and discontinuation on
Serum calcium, phosphorus and parathyroid hormone
Serum RANKL and osteoprotegerin (OPG), and RANKL/OPG levels
Effect of denosumab discontinuation, as measured by the following outcomes:
Biochemical markers of bone metabolism: beta-crosslaps C-telopeptides, procollagen-1 propeptide, bone specific alkaline phosphatase, osteocalcin, NTX-telopeptides
- Effect measured by change in other outcome measures, such as:
Bone density assessed by DXA
Physical Medicine and Rehabilitation evaluation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objectives:
The primary objective of this study is to evaluate the effect of denosumab on bone turnover in individuals with fibrous dysplasia (FD). Secondary objectives are to determine the effect of denosumab on bone pain, FD lesion intensity as revealed in 18F-sodium fluoride PET/CT bone scan, and to determine the effect of denosumab discontinuation on bone turnover re-bound after discontinuation.
Study Population:
Up to 14 adult subjects with FD may be enrolled to ensure complete study data on 9 subjects.
Design:
This study is a single center, open label pilot study of once-monthly dosing of denosumab. Subjects will be treated for 6 months, after which they will be followed by an 8-month observation period. A final visit will occur 21 months after denosumab discontinuation. Dosing will be adopted from studies in adults on treatment for giant cell tumors, with denosumab administered at 120 mg per dose every 4 weeks, with loading doses on days 7 and 14 of month 1.
Outcome Measures:
Primary:
Assessment of the effects of denosumab on:
1. Markers of bone turnover:
- Beta-crosslaps C-telopeptides (bone resorption marker)
- Procollagen-1-propeptide (bone formation marker)
Secondary:
Assessment of the effects of denosumab on:
Bone histomorphometric indices:
- Mineralized perimeter
- Bone formation rate
- Cortical width
- Cortical area
- Osteoid width
- Osteoid perimeter
- Mineral apposition rate
Surrogate markers of a direct therapeutic effect of denosumab on FD lesions:
- Semi-quantitative changes in RANKL, Ki67 (marker of cell proliferation), p16 (marker of cell senescence), and/or apoptosis index before and after treatment, as assessed by immunohistochemistry
- Changes in sentinel lesion intensity, measured quantitatively by uptake on 18Fsodium fluoride PET/CT bone scan.
- FD-related bone pain assessed by the Brief Pain Inventory (Short Form), a validated self-reporting tool for assessment of pain.
Exploratory Endpoints:
Effect of denosumab initiation and discontinuation on
- Serum calcium, phosphorus and parathyroid hormone
- Serum RANKL and osteoprotegerin (OPG), and RANKL/OPG levels
Effect of denosumab discontinuation, as measured by the following outcomes:
-Biochemical markers of bone metabolism: beta-crosslaps C-telopeptides, procollagen-1 propeptide, bone specific alkaline phosphatase, osteocalcin, NTX-telopeptides
Effect measured by change in other outcome measures, such as:
- Bone density assessed by DXA
- Physical Medicine and Rehabilitation evaluation
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA:
- Age > or equal to 18 years
- Skeletal maturity with fusion of epiphyses documented radiographically
- Concomitant enrollment in the companion Screening and Natural History protocol 98-D-0145
- Confirmed diagnosis of Fibrous Dysplasia
- Self-reported FD-related bone pain at a site of FD, present for at least 3 months
- Ability to understand and provide informed consent
- Willing and able to complete the protocol scheduled assessments and medication regimen
- Willing and able to take calcium and vitamin D supplements provided by NIH
- Women of child bearing potential must use two forms of acceptable contraception: hormonal contraception (birth control pills, injected hormones or vaginal ring); intrauterine device and/or barrier methods (condom or diaphragm) used with spermicide. Surgical sterilization (hysterectomy, tubal ligation, or vasectomy in a partner) is considered one form of contraception therefore only one other form of contraception will be required in these subjects. Verbal confirmation will be obtained at screening that two forms of acceptable contraception are being used, and that the subjects agree to use the two forms of contraception from the time they sign study consent through five months after study completion (19 months total).
- Serum calcium or albumin-adjusted serum calcium within the normal range for the NIH laboratory.
EXCLUSION CRITERIA:
- Administration of denosumab within the previous year
- Use of bisphosphonates within one year prior to first day of the denosumab administration (Day 0). Examples of bisphosphonates include: pamidronate (Aredia), Alendronate (Fosamax) and Zoledronate (Zomata).
- Prior history, or current evidence, of osteomyelitis/osteonecrosis of the jaw or presence of an active dental or jaw condition which requires oral surgery
- Planned invasive dental procedure for the course of the study
- Presence of non-healed dental or oral surgery
- Orthopedic procedure performed less than 12-weeks prior to first day of the denosumab administration (Day 0)
- Acute fracture less than 12-weeks prior to first day of the denosumab administration (Day 0)
- 25-hydroxyvitamin D level than 30 ng/mL (patients will be eligible for re-screening after a repletion period lasting no longer than 6 months)
- Untreated or inadequately treated hypophosphatemia, defined as serum phosphate levels below the NIH normal range (patients will be eligible for re-screening after initiation or optimization of phosphorus replacement no longer than 6 months)
- Subject is pregnant or breast feeding, or planning to become pregnant or breastfeed while on study and through 5 months after completion of treatment
- Use of another investigational agent within the last 3 months prior to the first day of the denosumab administration (Day 0)
- Subject has known sensitivity to any of the products to be administered during the study (e.g. polyketide antibiotics, mammalian derived products, calcium, or vitamin D)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Denosumab will be administered at 120 mg per dose every 4 weeks for six months, with loading doses on days 8 and 15 of month 1.
|
Denosumab will be administered at 120 mg per dose every 4 weeks for six months, with loading doses on days 8 and 15 of month 1.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary:1. Assessment of markers of bone turnover: Beta-crosslaps, C-telopeptides (bone resorption marker,Procollagen-1-propeptide (bone formation marker)
Time Frame: every 3 months
|
Assessment of the effects of denosumab on: 1. Markers of bone turnover: Beta-crosslaps C-telopeptides (bone resorption marker) & Procollagen-1-propeptide (bone formation marker)
|
every 3 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Secondary outcome #1- Bone histomorphometric indices: (SqrRoot) Mineralized perimeter, (SqrRoot) Bone formation rate (SqrRoot) Cortical width (SqrRoot) Cortical area (SqrRoot) Osteoid width...
Time Frame: 2 time points
|
2 time points
|
Secondary endpoint #3 - Pain assessments utilizing the Brief Pain Inventory scores
Time Frame: 2 time points
|
2 time points
|
Secondary Endpoint #2 - Surrogate markers of a direct therapeutic effect of denosumab on FD lesions:-Semi-quantitative changes in RANKL, Ki67 (marker of cell proliferation), p16 (marker od cell senescence), and/or apoptosis index-Sen...
Time Frame: 2-4 timepoints
|
2-4 timepoints
|
Exploratory endpoint #3 - Effect measured by change in other outcome measures(SqrRoot) Bone density assessed by DXA(SqrRoot) Physical Medicine and Rehabilitation evaluation
Time Frame: Q 3 mths/Q 6 mths
|
Q 3 mths/Q 6 mths
|
Exploratory endpoint #2 - Denosumab discontinuation effect on:(SqrRoot) Biochemical markers of bone metabolism: beta-crosslaps C-telopeptides, procollagen-1 propeptide, bone specific alkaline phosphatase, osteocalcin, NTX-telopeptides
Time Frame: every 3 months
|
every 3 months
|
Exploratory Endpoint # 1. Effect of denosumab initiation and discontinuation on(SqrRoot) Serum calcium, phosphorus and parathyroid hormone (SqrRoot) Serum circulating RANKL and osteoprotegerin (OPG), and RANKL/OPG level...
Time Frame: up to12 timepoints
|
up to12 timepoints
|
Collaborators and Investigators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 180114
- 18-D-0114
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
-
Cairo UniversityCompletedCervical Pain | Lumbar Pain SyndromeEgypt
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
Clinical Trials on Denosumab
-
AmgenCompletedOsteoporosis | Osteopenia | Low Bone Mineral Density | Low Bone Mass | Males With Osteoporosis
-
GlaxoSmithKlineCompletedOsteoporosis, PostmenopausalKorea, Republic of
-
Samsung Bioepis Co., Ltd.CompletedPostmenopausal OsteoporosisPoland
-
AmgenCompletedHealthy VolunteerUnited States
-
AmgenCompletedPostmenopausal OsteoporosisUnited States, Denmark, Poland, Canada
-
Borstkanker Onderzoek GroepAmgenWithdrawn
-
Swiss Group for Clinical Cancer ResearchActive, not recruitingMetastatic Breast Cancer | Bone Metastases | Metastatic Prostate CancerSwitzerland, Germany, Austria
-
Luye Pharma Group Ltd.ParexelCompleted
-
National Cancer Institute (NCI)TerminatedOvarian CarcinomaUnited States, Israel